GIVAX

Executive Summary

GIVAX is a private biotech company based in Cambridge, MA, founded in 2021, dedicated to developing novel vaccines against rotavirus and norovirus, which cause severe gastroenteritis in children. Leveraging its proprietary platform technology, GIVAX aims to create a new class of vaccines that could address significant unmet medical needs in pediatric infectious diseases. The company's approach focuses on transforming vaccine development through innovative viral technology, potentially offering improved efficacy and broader protection compared to existing vaccines. As a early-stage company with no disclosed funding or pipeline details, GIVAX represents a high-risk, high-reward opportunity in the vaccine space, with its success hinging on preclinical and clinical validation of its platform.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical proof-of-concept studies60% success
• Q1 2027IND submission for lead vaccine candidate40% success
• Q4 2026Strategic partnership or licensing deal30% success